Tellus BioVentures

Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for severe autoimmune diseases through targeted therapies. The company's lead candidate, DNTH103, is a monoclonal antibody designed to selectively inhibit a specific component of the immune system, offering potential advantages over existing complement therapies. This treatment aims to improve safety and efficacy for patients suffering from serious autoimmune and inflammatory conditions. Dianthus is committed to advancing its pipeline of next-generation complement therapeutics, supported by a team of experienced professionals in the biotech and pharmaceutical sectors. The company envisions that DNTH103 could be administered as a self-injection for certain patients, enhancing convenience and accessibility in treatment.

Cantai Therapeutics operates as a developer of drug candidates.

Vittoria Biotherapeutics is a biotechnology company focused on developing gene-edited T-cell therapies to address unmet medical needs in oncology and autoimmune diseases. It utilizes Senza5 technology to enhance the efficacy, safety, and practical utility of cell-based therapeutics, aiming to lower dosing requirements, ease preconditioning regimens, reduce manufacturing failures, and shorten vein-to-vein times. By expanding the potential applications of T-cell therapies, the company seeks to improve patient outcomes across its therapeutic pipeline and advance next-generation cell-based treatments from research toward clinical use.

Praeventix is an early-stage biotechnology company dedicated to developing innovative therapeutics for bowel diseases and other serotonergic-driven disorders. The company specializes in the discovery, research, and early clinical development of novel therapeutics that modulate signal transduction pathways. Praeventix aims to address unmet clinical needs in inflammatory bowel disease and has potential applications in treating dermatologic, autoimmune, and neurodegenerative diseases. Through its focused approach, the company seeks to provide physicians with effective treatment options for conditions such as chronic pruritus.

Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing immune-based therapies for autoimmune and immune-mediated diseases. Based in Florida, United States, the company advances biologic programs and aims to modulate B cell–driven pathology. Its lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb on B cells, thereby inhibiting harmful immune activity without depleting B cells.

Vittoria Biotherapeutics is a biotechnology company focused on developing gene-edited T-cell therapies to address unmet medical needs in oncology and autoimmune diseases. It utilizes Senza5 technology to enhance the efficacy, safety, and practical utility of cell-based therapeutics, aiming to lower dosing requirements, ease preconditioning regimens, reduce manufacturing failures, and shorten vein-to-vein times. By expanding the potential applications of T-cell therapies, the company seeks to improve patient outcomes across its therapeutic pipeline and advance next-generation cell-based treatments from research toward clinical use.

Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for severe autoimmune diseases through targeted therapies. The company's lead candidate, DNTH103, is a monoclonal antibody designed to selectively inhibit a specific component of the immune system, offering potential advantages over existing complement therapies. This treatment aims to improve safety and efficacy for patients suffering from serious autoimmune and inflammatory conditions. Dianthus is committed to advancing its pipeline of next-generation complement therapeutics, supported by a team of experienced professionals in the biotech and pharmaceutical sectors. The company envisions that DNTH103 could be administered as a self-injection for certain patients, enhancing convenience and accessibility in treatment.

Navrogen is a biopharmaceutical company focused on targeted cancer treatment by addressing tumor-produced factors that suppress the humoral immune response and limit antibody-based therapies. The company develops technology platforms to identify proteins produced by tumors that inhibit endogenous humoral immunity against cancer cells, enabling physicians to discover and assemble a database of tumor types that overcome these immunosuppressive effects. This approach seeks to improve the efficacy of cancer immunotherapies by informing precision treatment strategies and identifying patient-specific tumor profiles. Based in Philadelphia, Navrogen aims to advance understanding of tumor immunology and translate these insights into targeted interventions.

Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas. Intravenous in vivo CAR treatment, which treats B cell lymphomas, is the company's flagship program. Its unique engineering provides exceptional target tissue specificity. The business is working on a second initiative to address autoimmune conditions. With the help of Interius, a novel and distinct therapeutic modality for the precise administration of gene therapies may soon be made available to patients in expanded care settings, without the need for preconditioning chemotherapy.

Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing immune-based therapies for autoimmune and immune-mediated diseases. Based in Florida, United States, the company advances biologic programs and aims to modulate B cell–driven pathology. Its lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb on B cells, thereby inhibiting harmful immune activity without depleting B cells.

TamuroBio is a biotechnology company dedicated to developing innovative therapeutics for non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and Type 2 diabetes. The company focuses on creating pre-clinical candidates aimed at sequestering lipotoxic products to treat NASH, thereby helping patients prevent chronic liver disease and improve their quality of life. Through its targeted research and development efforts, TamuroBio aims to address significant unmet medical needs in the management of these conditions.

Founded in 2013, Aegle Therapeutics is a biotechnology company developing extracellular vesicle (EV) therapies derived from mesenchymal stem cells. Its lead product aims to treat dystrophic epidermolysis bullosa, a rare pediatric skin disorder, by promoting healing and reducing scarring.

Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas. Intravenous in vivo CAR treatment, which treats B cell lymphomas, is the company's flagship program. Its unique engineering provides exceptional target tissue specificity. The business is working on a second initiative to address autoimmune conditions. With the help of Interius, a novel and distinct therapeutic modality for the precise administration of gene therapies may soon be made available to patients in expanded care settings, without the need for preconditioning chemotherapy.